Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers
- PMID: 3018242
- DOI: 10.1021/jm00159a014
Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers
Abstract
Bivalent ligands 1-4 with naltrexamine pharmacophores and spacers of different lengths containing a fumaryl moiety were synthesized and evaluated for mu and kappa opioid antagonist activity on the electrically stimulated guinea pig ileal longitudinal muscle (GPI). The fumaryl moiety was incorporated into the spacer in order to determine the effect of conformational restriction of the spacer on the relationship between spacer length and opioid antagonist potency. While it was found that the fumaryl and succinyl series (11) possessed a very similar structure-potency profile with respect to antagonism at mu opioid receptors, the interaction of these two series at kappa receptors differed substantially from one another. This difference was manifested by the longer spacer requirement for peak kappa antagonist potency in the fumaryl relative to the succinyl series. It is concluded that the conformational restriction imposed by the fumaryl group in a short spacer (n = 0) prevents effective interaction of both pharmacophores with vicinal recognition sites of the kappa receptor system; as the spacer is lengthened (n = 2) and becomes more flexible, the simultaneous occupation of vicinal recognition sites occurs with greater facility.
Similar articles
-
Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors.J Med Chem. 1986 Oct;29(10):1855-61. doi: 10.1021/jm00160a010. J Med Chem. 1986. PMID: 3020244
-
Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine.J Med Chem. 1988 Jul;31(7):1344-7. doi: 10.1021/jm00402a015. J Med Chem. 1988. PMID: 2838632
-
Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity.J Med Chem. 1988 Apr;31(4):836-41. doi: 10.1021/jm00399a026. J Med Chem. 1988. PMID: 2832604
-
Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.J Med Chem. 1998 Jul 16;41(15):2872-81. doi: 10.1021/jm980083i. J Med Chem. 1998. PMID: 9667975
-
Recent developments in the design of receptor specific opioid peptides.Med Res Rev. 1989 Jul-Sep;9(3):343-401. doi: 10.1002/med.2610090306. Med Res Rev. 1989. PMID: 2547125 Review. No abstract available.
Cited by
-
The crosstalk between 5-HT2AR and mGluR2 in schizophrenia.Neuropharmacology. 2023 Jun 1;230:109489. doi: 10.1016/j.neuropharm.2023.109489. Epub 2023 Mar 6. Neuropharmacology. 2023. PMID: 36889432 Free PMC article. Review.
-
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.Bioorg Med Chem. 2011 May 1;19(9):2808-16. doi: 10.1016/j.bmc.2011.03.052. Epub 2011 Mar 26. Bioorg Med Chem. 2011. PMID: 21482470 Free PMC article.
-
Kappa opioid antagonists: past successes and future prospects.AAPS J. 2005 Oct 27;7(3):E704-22. doi: 10.1208/aapsj070371. AAPS J. 2005. PMID: 16353947 Free PMC article. Review.
-
2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.J Med Chem. 2020 Mar 12;63(5):1779-1797. doi: 10.1021/acs.jmedchem.9b01105. Epub 2019 Sep 24. J Med Chem. 2020. PMID: 31499001 Free PMC article.
-
A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors.Bioorg Med Chem Lett. 2009 Dec 15;19(24):6978-80. doi: 10.1016/j.bmcl.2009.10.045. Epub 2009 Nov 4. Bioorg Med Chem Lett. 2009. PMID: 19892550 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials